Cargando…

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors

Detalles Bibliográficos
Autores principales:	Chen, Yan, Yang, Zhi, Gao, Xueyun, Zhu, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568177/ https://www.ncbi.nlm.nih.gov/pubmed/37842662 http://dx.doi.org/10.1016/j.jpha.2023.08.007

Ejemplares similares

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Analysis of the expression and genetic alteration of CLDN18 in gastric cancer
por: Li, Jian, et al.
Publicado: (2020)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
por: Huang, Yufan, et al.
Publicado: (2023)

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models
por: Konno, Hiroyasu, et al.
Publicado: (2022)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer
por: Matsusaka, Keisuke, et al.
Publicado: (2016)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family
por: Gao, Peipei, et al.
Publicado: (2021)

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults
por: Nakayama, Izuma, et al.
Publicado: (2019)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
por: Zhang, Zhenfa, et al.
Publicado: (2013)

Membranous and nuclear staining of CLDN18 in HPV‐independent and HPV‐associated endocervical adenocarcinomas
por: Du, Xiuzhen, et al.
Publicado: (2022)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications
por: Kwon, Mi Jeong, et al.
Publicado: (2010)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Molecular dynamics analyses of CLDN15 pore size and charge selectivity
por: McGuinness, Sarah, et al.
Publicado: (2023)

DNA Sequence-Mediated, Evolutionarily Rapid Redistribution of Meiotic Recombination Hotspots: Commentary on Genetics 182: 459–469 and Genetics 187: 385–396
por: Wahls, Wayne P., et al.
Publicado: (2011)

CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis
por: Zhang, Wei-na, et al.
Publicado: (2016)

The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells
por: Lu, Yan, et al.
Publicado: (2021)

Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
por: Wang, Fujun, et al.
Publicado: (2023)

A braided cancer river connects tumor heterogeneity and precision medicine
por: Hsieh, James J., et al.
Publicado: (2016)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Molecular cloning and characterisation of chicken IL-18 binding protein
por: Gibson, Mark S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fvum4u0735ooql58strt64pdg9